What does Dendrogenix do?
DENDROGENIX specializes in advanced dendritic cell technologies for immunotherapy applications. The company develops innovative solutions to enhance immune responses against cancer and infectious diseases. By leveraging cutting-edge research, DENDROGENIX aims to improve patient outcomes through targeted therapies.
- Signals
-
Reporting lossesReporting losses € -2.29M
The company reported a loss in the latest financial year.
Negative cashflowNegative cashflow € -215KOperating cash flow was negative in the latest financial year.
Negative EBITDANegative EBITDA € -1.58MEBITDA is negative: operating activities are loss-making.
Strong equityStrong equity € 3.29MStrong equity provides a buffer against setbacks.
Low riskLow risk 62.4%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 8.38A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Healthy social debtHealthy social debt 10.4%Social debts stay manageable relative to personnel costs.
- Shareholders
- Noshaq Spin-Offs 20,37%, Wallonie Entreprendre 10,12%
Financial ratios
|
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
€
-626K
|
€
-687K
|
€
-1.50M
|
€
-917K
|
|
|
€
-1.58M
|
€
-1.76M
|
€
-2.59M
|
€
-1.71M
|
|
|
€
-2.29M
|
€
-2.22M
|
€
-2.84M
|
€
-3.52M
|
|
|
€
3.29M
|
€
5.59M
|
€
7.67M
|
€
3.51M
|
|
|
62.36%
|
72.83%
|
74.11%
|
77.27%
|
|
|
€
1.99M
|
€
2.09M
|
€
2.68M
|
€
1.03M
|
|
|
€
3.29M
|
€
5.45M
|
€
7.31M
|
€
2.83M
|
|
|
7.70
|
8.90
|
6.90
|
6.00
|
Publications 11
All publications- Statuts (Traduction, Coordination, Autres Modifications, ) - Capital, Actions - Demissions, Nominations 28/12/2023
- Capital, Actions - Demissions, Nominations 20/03/2023
- Statuts (Traduction, Coordination, Autres Modifications, ) - Capital, Actions - Demissions, Nominations 07/10/2022
- Demissions, Nominations 01/04/2022
- Capital, Actions 01/03/2022
Frequently asked questions
Answers to the most common questions about Dendrogenix, based on official government data and the filed annual accounts.
What is the VAT number of Dendrogenix?
The VAT number of Dendrogenix is BE0700.613.677.
How many employees work at Dendrogenix?
In 2025, Dendrogenix employed 7.70 full-time equivalents (FTE).
When was Dendrogenix established?
Dendrogenix was founded in 02-08-2018.
What is the official address of Dendrogenix?
The official address of Dendrogenix is Avenue De L'hôpital 11 Liège 4000 Sps Bâtiment 34, 3E Étage.
What is the legal form of Dendrogenix?
The juridical form of Dendrogenix is Public limited company (NV/SA).
What is the annual revenue of Dendrogenix?
The 2025 accounts of Dendrogenix do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does Dendrogenix do?
DENDROGENIX specializes in advanced dendritic cell technologies for immunotherapy applications. The company develops innovative solutions to enhance immune responses against cancer and infectious diseases. By leveraging cutting-edge research, DENDROGENIX aims to improve patient outcomes through targeted therapies.
Is Dendrogenix a reliable company?
Dendrogenix is a registered Rechtspersoon with company number 0700.613.677 and can be verified through the official CBE database.
What is the credit limit of Dendrogenix?
The estimated credit limit of Dendrogenix is €160,438.
Is Dendrogenix still active?
Dendrogenix currently has the status "Normal situation" and is active.